N-(4-chlorophenyl)-4-formylbenzenesulfonamide | 816450-54-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-chlorophenyl)-4-formylbenzenesulfonamide
• 英文别名: Benzenesulfonamide, N-(4-chlorophenyl)-4-formyl-
• CAS: 816450-54-1
• 化学式: C₁₃H₁₀ClNO₃S
• 分子量: 295.746
• InChiKey: VJSMYBYLVBTCFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-chlorophenyl)-4-formylbenzenesulfonamide 、 3,4-二氨基苯甲酰胺 在 sodium metabisulfite 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以84%的产率得到2-[4-(4-Chloro-phenylsulfamoyl)-phenyl]-1H-benzoimidazole-5-carboxylic Acid Amide
  参考文献：
  名称：

  Checkpoint Kinase Inhibitors:  SAR and Radioprotective Properties of a Series of 2-Arylbenzimidazoles

  摘要：

  The discovery of a series of novel, potent, and highly selective inhibitors of the DNA damage control kinase chk2 is disclosed. Here we report the first SAR study around inhibitors of this kinase. High-throughput screening of purified human chk2 led to the identification of a novel series of 2-arylbenzimidazole inhibitors of the kinase. Optimization was facilitated using homology models of chk2 and docking of inhibitors, leading to the highly potent 2-arylbenzimidazole 2h (IC50 15 nM). Compound 2h is an ATP-competitive inhibitor of chk2 that dose dependently protects human CD4+ and CD8+ T-cells from apoptosis due to ionizing radiation. This work suggests that a selective small molecule inhibitor of chk2 could be a useful adjuvant to radiotherapy, increasing the therapeutic window of such treatment.

  DOI：

  10.1021/jm0495935
• 作为产物：
  描述：

  4-甲酰基苯磺酰氯 、 对氯苯胺 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以65%的产率得到N-(4-chlorophenyl)-4-formylbenzenesulfonamide
  参考文献：
  名称：

  Checkpoint Kinase Inhibitors:  SAR and Radioprotective Properties of a Series of 2-Arylbenzimidazoles

  摘要：

  The discovery of a series of novel, potent, and highly selective inhibitors of the DNA damage control kinase chk2 is disclosed. Here we report the first SAR study around inhibitors of this kinase. High-throughput screening of purified human chk2 led to the identification of a novel series of 2-arylbenzimidazole inhibitors of the kinase. Optimization was facilitated using homology models of chk2 and docking of inhibitors, leading to the highly potent 2-arylbenzimidazole 2h (IC50 15 nM). Compound 2h is an ATP-competitive inhibitor of chk2 that dose dependently protects human CD4+ and CD8+ T-cells from apoptosis due to ionizing radiation. This work suggests that a selective small molecule inhibitor of chk2 could be a useful adjuvant to radiotherapy, increasing the therapeutic window of such treatment.

  DOI：

  10.1021/jm0495935

文献信息

• 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them
  申请人：MAUGER Jacques

  公开号：US20080261969A1

  公开（公告）日：2008-10-23

  This invention relates to compounds of formula (I) to processes for the preparation of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment comprising administering of such compounds.

  本发明涉及式(I)化合物、制备该类化合物的方法、包含该类化合物的药物组合物，以及通过给予该类化合物的治疗方法。
• 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
  申请人：Aventis Pharma S.A.

  公开号：EP1746097B1

  公开（公告）日：2010-01-13
• 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM
  申请人：Aventis Pharma S.A.

  公开号：EP1910366A2

  公开（公告）日：2008-04-16
• US8163768B2
  申请人：——

  公开号：US8163768B2

  公开（公告）日：2012-04-24
• [EN] 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM<br/>[FR] HETEROCYCLES FUSIONNES DE 1,4-DIHYDROPYRIDINE, PROCEDE POUR PREPARER CEUX-CI, UTILISATIONS ET COMPOSITIONS LES CONTENANT
  申请人：AVENTIS PHARMA SA

  公开号：WO2007012972A2

  公开（公告）日：2007-02-01

  [EN] 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them. The invention is about substituted dihydropyridine-fused heterocycles useful for the treatment of cancer disease, especially for preventing cancerous cells to divide. These compounds act as inhibitors of Aurora A and/or B kinases. Formula (I).
  [FR] L'invention concerne des hétérocycles fusionnés de 1,4-dihydropyridine, un procédé pour préparer ceux-ci, ainsi que leurs utilisations et des compositions les contenant. L'invention concerne des hétérocycles fusionnés de dihydropyridine utiles pour traiter un cancer, en particulier pour éviter une division de cellules cancéreuses. Ces composés servent d'inhibiteurs aux kinases Aurora A et/ou B. Formule (I).